530 related articles for article (PubMed ID: 20578166)
1. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
[TBL] [Abstract][Full Text] [Related]
3. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
Bugiardini R; Dorobantu M; Vasiljevic Z; Kedev S; Knežević B; Miličić D; Calmac L; Trninic D; Daullxhiu I; Cenko E; Ricci B; Puddu PE; Manfrini O; Koller A; Badimon L;
Atherosclerosis; 2015 Jul; 241(1):151-6. PubMed ID: 25988359
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
[TBL] [Abstract][Full Text] [Related]
9. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Zeymer U; Gitt A; Zahn R; Jünger C; Bauer T; Heer T; Koeth O; Senges J
EuroIntervention; 2009 Jan; 4(4):524-8. PubMed ID: 19284076
[TBL] [Abstract][Full Text] [Related]
11. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
[TBL] [Abstract][Full Text] [Related]
13. Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
Moliterno DJ
Catheter Cardiovasc Interv; 2011 Feb; 77(2):191-2. PubMed ID: 21290553
[No Abstract] [Full Text] [Related]
14. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
18. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
